You are here

Press Release Archive

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Wednesday, June 11th at 10:40 a.m. Pacific Daylight Saving Time. To  view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the

 
- Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex by Generic Manufacturer Teva

(BUSINESS WIRE)--Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. The panel ruled that the patents (Nos. 5,466,823 and 5,563,165) covering the

 
- Pfizer Presents New Opportunities for Global Growth

(BUSINESS WIRE) Pfizer Inc today reviewed strategies to accelerate and refocus Pfizer’s pipeline and capture new opportunities for global growth at a meeting for investment analysts. “We have made real changes in how we operate our business – in our structure, culture and leadership – so that we have a much stronger foundation in place for pursuing the many opportunities before us,” said Chairman

 
- Pfizer Names William Ringo Senior Vice President of Strategy and Business Development

(BUSINESS WIRE) Pfizer Inc today named William Ringo as the company’s new Senior Vice President of Strategy and Business Development with responsibility for guiding Pfizer’s overall strategic planning and business development activities, reporting to Chairman and Chief Executive Officer Jeff Kindler. He will join Pfizer’s Executive Leadership Team. Mr. Ringo is a senior corporate bio-pharmaceutical executive with

 
- Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform

(BUSINESS WIRE) Pfizer Inc today announced that it has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate and an extensive compound library that targets Heat Shock Protein 90 (Hsp90), an exciting target in the fight against cancer. As per the agreement, Pfizer will acquire the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase I trials for the

 
- Pfizer to Seek to Appeal Lipitor Enantiomer Patent Ruling in the Netherlands, Company Notes That Ruling Has No Commercial Impact

(BUSINESS WIRE)-- Pfizer Inc said today that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that Pfizer’s atorvastatin enantiomer patent is invalid. The patent (EP 409,281) had been challenged by generics manufacturer Ranbaxy and expires in July 2010. The decision has no commercial impact because Pfizer’s basic patent covering Lipitor (EP 247,633) remains in force and expires

 
- Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik

(BUSINESS WIRE)--Pfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion. Commenting on the withdrawal of the Jarvik advertising and promotion, Pfizer’s President of Worldwide Pharmaceutical Operations Ian Read said

 
- Appellate Court in the Netherlands Upholds Basic Lipitor Patent, Prevents Launch of Ranbaxy Product before November 2011

(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision prevents Ranbaxy from launching its drug before Lipitor’s basic patent (EP 247,633) expires in November 2011. “Today’s decision is

 
- Pfizer to Acquire Encysive Pharmaceuticals

(BUSINESS WIRE)--NEW YORK

 
- Pan-African Conference Focuses on Keeping the Medicine Supply in Africa Safe

(BUSINESS WIRE)--An international conference to discuss the issue of counterfeit medicines in Africa started this week in Johannesburg. The aim of the conference, which is sponsored by Pfizer, is for representatives from sub-Saharan countries to discuss the threats that counterfeit medicines and unregistered generics pose for the safety of patients in this region and to develop joint plans of action to address this issue

 
- Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on Retroviruses and Opportunistic Infections

(BUSINESS WIRE)--At this week’s major HIV/AIDS research meeting, Pfizer presented new data on two investigational second generation HIV compounds – a CCR5 antagonist and a non-nucleoside reverse transcriptase inhibitor (NNRTI). Pfizer also presented additional data on SelzentryTM (maraviroc) tablets, its first-in-class medicine approved last year for use in treatment-experienced HIV patients infected with a certain type of

 
- Pfizer Japan Receives Manufacturing and Marketing Authorization for Champix(R)

(BUSINESS WIRE)--Pfizer Japan Inc (headquarter in Shibuya-ku, Tokyo; headed by President & Chief Executive Officer, Hiromitsu Iwasaki; and capitalized at Yen 64.8 billion) announced that on January 25, the company received manufacturing and marketing authorization for Champix® Tablet 0.5 mg/1mg (varenicline tartrate), a smoking cessation aid for smokers dependent on nicotine. Champix is Japan’s first oral smoking

 
- Pfizer Reports Fourth-Quarter and Full-Year 2007 Results and 2008 Financial Guidance

Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts) Fourth Quarter Full Year 2007 2006 Change

 
- Make a New Year's Resolution to Lose Weight - For Your Dog

(BUSINESS WIRE)--As millions of Americans vow to get healthier and stave off illness by making a New Year’s resolution to lose weight, it’s time for dog owners to make a similar pledge for their furry friends. Recent studies indicate that 25 to 40 percent of U.S. dogs – approximately 17 million – are overweight or obese and potentially facing serious health problems. What’s more troubling is that

 
- Pfizer Invites Public to View and Listen to Webcast of March 5 Meeting with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on Wednesday, March 5, at 8:30a.m. Eastern Standard Time. The purpose of the meeting is to discuss the Company’s strategic direction. Jeffrey B. Kindler, Pfizer chairman and chief executive officer, will host the meeting. To view and listen to the webcast, visit our web site

 
- Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States

(BUSINESS WIRE)--Cigarette smoking is associated with significant morbidity and mortality. Smoking is the leading preventable cause of disease and premature death in the United States, with more than 438,000 U.S. deaths annually attributable to smoking. Patients who smoke cigarettes should be counseled to quit. CHANTIX® was approved in May of 2006 in the U.S. as an aid to smoking cessation. Based upon post-marketing reports

 
- Pfizer Reaffirms Leadership in International Corporate Volunteerism by Deploying the Largest Round of Global Health Fellows

(BUSINESS WIRE)-- Pfizer Inc today announced the eighth class of Global Health Fellows, a group of 28 Pfizer colleagues from North America, Europe and Asia, who will partner with non-governmental organizations (NGOs) and multilateral organizations (MLOs) in developing countries to help build health care infrastructure while on dedicated 4-6 month assignments. The Pfizer Global Health Fellows program is one of the first public-

 
- Adding Lipitor Early to Effective Blood Pressure Treatment Provided a Significant Reduction in Heart Attacks or Deaths from Heart Attacks over Five Years

(BUSINESS WIRE)--The early addition of Lipitor® (atorvastatin calcium) Tablets to effective blood pressure lowering treatment maintained a significant 36 percent reduction in the relative risk of fatal or non-fatal heart attacks over five years, according to a new analysis. This was a post-hoc analysis (designed and completed following the closure of the trial) of the lipid-lowering arm of the Anglo-Scandinavian Cardiac

 
- Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil’s cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligible for

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.